REZIPAS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rezipas, and when can generic versions of Rezipas launch?
Rezipas is a drug marketed by Bristol Myers Squibb and is included in one NDA.
The generic ingredient in REZIPAS is aminosalicylic acid resin complex. There are fifteen drug master file entries for this compound. Additional details are available on the aminosalicylic acid resin complex profile page.
Summary for REZIPAS
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 151 |
Patent Applications: | 3,374 |
Formulation / Manufacturing: | see details |
DailyMed Link: | REZIPAS at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for REZIPAS
US Patents and Regulatory Information for REZIPAS
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | REZIPAS | aminosalicylic acid resin complex | POWDER;ORAL | 009052-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |